{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:07:06Z","timestamp":1792069626656,"version":"4.4.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/cld.0000000000000015","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T13:00:59Z","timestamp":1682600459000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Review of the role of statins in cirrhosis and portal hypertension"],"prefix":"10.1097","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-7238","authenticated-orcid":false,"given":"Jordi","family":"Gratac\u00f3s-Gin\u00e8s","sequence":"first","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEReHD), Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-7686","authenticated-orcid":false,"given":"Elisa","family":"Pose","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Cl\u00ednic de Barcelona, University of Barcelona, Barcelona, Catalonia, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEReHD), Barcelona, Catalonia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"R1-20241015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R2-20241015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: a Nationwide Cohort Study","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R3-20241015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","article-title":"Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES","volume":"64","author":"Simon","year":"2016","journal-title":"Hepatology"},{"key":"R4-20241015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"R5-20241015","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"R7-20241015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","article-title":"Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study","volume":"66","author":"Chang","year":"2017","journal-title":"Hepatology"},{"key":"R8-20241015","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","article-title":"Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study","volume":"46","author":"Bang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20241015","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jhep.2021.12.034","article-title":"Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort","volume":"76","author":"Mahmud","year":"2022","journal-title":"J Hepatol"},{"key":"R10-20241015","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes","year":"2016","journal-title":"Gastroenterology"},{"key":"R11-20241015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis q","volume":"69","author":"Angeli","year":"2018","journal-title":"J Hepatol"},{"key":"R12-20241015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes","year":"2009","journal-title":"Gastroenterology"},{"key":"R13-20241015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores","year":"2015","journal-title":"Dig Liver Dis"},{"key":"R14-20241015","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension","volume":"30","author":"Bishnu","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R15-20241015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial","volume":"115","author":"Vijayaraghavan","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R16-20241015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4254\/wjh.v9.i5.270","article-title":"Addition of simvastatin to carvedilol non responders: a new pharmacological therapy for treatment of portal hypertension","volume":"9","author":"Wani","year":"2017","journal-title":"World J Hepatol"},{"key":"R17-20241015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J Hepatol"},{"issue":"8A","key":"R18-20241015","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"R19-20241015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcp.12182","article-title":"CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores","volume":"77","author":"Albarmawi","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20241015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(19)30320-6","article-title":"Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Pose","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R21-20241015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol Res"},{"key":"R22-20241015","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/hep4.2022","article-title":"Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study","volume":"6","author":"Yun","year":"2022","journal-title":"Hepatol Commun"},{"key":"R23-20241015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R24-20241015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","article-title":"Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis","volume":"150","author":"Mohanty","year":"2016","journal-title":"Gastroenterology"},{"key":"R25-20241015","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s10620-014-3179-2","article-title":"Statin use in patients with cirrhosis: a retrospective cohort study","volume":"59","author":"Kumar","year":"2014","journal-title":"Dig Dis Sci"},{"key":"R26-20241015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/apt.12430","article-title":"Statin use and infections in Veterans with cirrhosis","volume":"38","author":"Motzkus-Feagans","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R27-20241015","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1007\/s10620-020-06630-7","article-title":"safety of chronic simvastatin treatment in patients with decompensated cirrhosis: many adverse events but no liver injury","volume":"66","author":"Mu\u00f1oz","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R28-20241015","first-page":"194","article-title":"Old drugs as new therapy for liver diseases? J Hepatol","volume":"70","author":"Pose","year":"2019"}],"container-title":["Clinical Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CLD.0000000000000015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T22:09:41Z","timestamp":1729030181000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CLD.0000000000000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/cld.0000000000000015","relation":{},"ISSN":["2046-2484"],"issn-type":[{"value":"2046-2484","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"2022-09-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}